Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.65 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.65 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.65 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13050975 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL12356559 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL742137 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL1903431 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL1903432 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL3745309 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL2820396 | 0.85 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL335652 | 0.83 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL6339022 | 0.83 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL900113 | 0.83 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4188924-B1 | ANTAGONIST COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-06-18 | — | — | EP | claimed |
| EP-2268646-A2 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2011-01-05 | — | — | EP | claimed |
| WO-2009126806-A2 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | WO | claimed |
| US-12473301-B2 | Isoquinoline compounds for the treatment of cancer | GENENTECH, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4602038-A1 | SULFOXIMINE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2025-08-20 | — | — | EP | disclosed |
| CN-119930589-A | Tricyclic compound, pharmaceutical composition and application | 广州国家实验室 | 2025-05-06 | — | — | CN | disclosed |
| EP-3860995-B1 | ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2025-04-16 | — | — | EP | disclosed |
| CN-113135896-B | Methylpyrazole derivatives as RET inhibitors | 正大天晴药业集团股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| WO-2024079682-A1 | SULFOXIMINE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-04-18 | — | — | WO | disclosed |
| EP-4308097-A1 | NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE | The Regents Of The University Of Michigan (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197690-A1 | NON-HYDROXAMATE HDAC6 INHIBITORS AND RELATED METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20210332064-A1 | ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2021-10-28 | — | — | US | disclosed |
| US-8357684-B2 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-22 | — | — | US | disclosed |
| US-20110190503-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICAL NV | 2011-08-04 | — | — | US | disclosed |
| US-20110159563-A1 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICAL NV | 2011-06-30 | — | — | US | disclosed |
| US-7939527-B2 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-10 | — | — | US | disclosed |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473301-B2 | Isoquinoline compounds for the treatment of cancer | PGK1, PHKG1, NEK1 | CHRNB2 3942/4885CHRNA4 4306/4885CHRNA3 4143/4885 |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | CHRNB2 2274/4885CHRNA4 1072/4885CHRNA3 2432/4885 |
| US-20110159563-A1 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | CHRNB2 1858/4885CHRNA4 671/4885CHRNA3 1831/4885 |
| US-20110190503-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | CHRNB2 2274/4885CHRNA4 1072/4885CHRNA3 2432/4885 |
| US-20210332064-A1 | ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | PGK1, PHKG1, NEK1 | CHRNB2 3942/4885CHRNA4 4306/4885CHRNA3 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.